Dexcel Pharma

Dexcel Pharma Overview

Dexcel Pharma is a pharmaceutical company engaged in the discovery, development, manufacture, and commercialization of innovative pharmaceutical products based on its proprietary controlled-release technologies. Dexcel Pharma develops novel formulations of existing molecules for large therapeutic markets. The companys aim is to provide meaningful clinical benefits for patients with chronic diseases. For example, the companys PerioChip product offers a new approach to treating gum disease by using a small chip inserted under the gums. Dexcel Pharmas development pipeline includes more than 30 novel 505(b)2 formulations and complex generics, targeting markets in the U.S. and the EU.

Latest News

Apr 1, 2014 · www.globes.co.il

growth-positive

Kitov Pharma signs Dexcel hypertension drug deal

Kitov Pharmaceutical Holdings Ltd. has signed a strategic cooperation agreement with Dexcel Pharma Ltd. to develop and produce its treatment for hypertension, KIT-302. Kitov is preparing a Phase III clinical trial of the drug. Dexcel will develop the drugs final formulation for the filing of a New Drug Application (NDA) with the US Food and Drug Administration (FDA). Kitov will pay Dexcel $2 million in cash and $1.5 million in shares to use the companys facilities.

PartnersInvestment

Funding

Team Members

5

Employees: 500+

Web & Social Links

Locations

HaKidma 10, Yokneam, Israel

Dexcel Street 1, Or Akiva, Israel

Nakhum Khaftsadi Street 21, Jerusalem, Israel

Carl-Zeiss-Strae 2, Alzenau, Germany

7 Sopwith Way, Daventry, UK

4 Loyang Way 1, Singapore

Photos & Videos

2 item(s)

Dexcel Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info